Ossianix Inc
09/04/2018 | Press release | Archived content
Ossianix - Novo Nordisk Press Release
Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases
PHILADELPHIA, PA, USA: Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain.
Under the terms of the agreement, Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products.
Under the terms of the agreement, Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products.
You can read the full press release here
Ossianix Inc published this content on September 04, 2018, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 11, 2026 at 06:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]